共 104 条
[1]
Amin DN(2010)The role of HER3, the unpretentious member of the HER family, in cancer biology and cancer therapeutics Semin Cell Dev Biol 21 944-950
[2]
Campbell MR(2009)Structural analysis of the catalytically inactive kinase domain of the human EGF receptor 3 Proc Natl Acad Sci U S A 106 21608-21613
[3]
Moasser MM(2003)The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation Proc Natl Acad Sci U S A 100 8933-8938
[4]
Jura N(2013)An antibody that locks HER3 in the inactive conformation inhibits tumor growth driven by HER2 or neuregulin Cancer Res 73 6024-6035
[5]
Shan Y(2011)Trastuzumab has preferential activity against breast cancers driven by HER2 homodimers Cancer Res 71 1871-1882
[6]
Cao X(2013)Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study Lancet Oncol 14 461-471
[7]
Shaw DE(2012)Potential therapeutic significance of HER-family in esophageal squamous cell carcinoma Ann Thorac Cardiovasc Surg 18 506-513
[8]
Kuriyan J(2012)Pharmacological strategies to overcome HER2 cross-talk and Trastuzumab resistance Curr Med Chem 19 1065-1075
[9]
Holbro T(2010)Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial Lancet 376 687-697
[10]
Beerli RR(2011)Neuregulin-1-mediated autocrine signaling underlies sensitivity to HER2 kinase inhibitors in a subset of human cancers Cancer Cell 20 158-172